Hetrombopag

Hetrombopag
INN: Hetrombopag
Clinical data
Trade names	Hengqu
Other names	Rafutrombopag olamine; rafutrombopag ethanolamine; hetrombopag; SHR-8735; SHR8735
Routes of; administration	Oral
Legal status
Legal status	In general: ℞ (Prescription only);
Identifiers
	IUPAC name 5-[2-Hydroxy-3-[[5-methyl-3-oxo-2-(5,6,7,8-tetrahydronaphthalen-2-yl)-1H-pyrazol-4-yl]diazenyl]phenyl]furan-2-carboxylic acid;
CAS Number	2600513-51-5 ; 1257792-42-9 (rafutrombopag olamine);
PubChem CID	135565610;
IUPHAR/BPS	10657;
DrugBank	DB16184;
ChemSpider	52084807;
UNII	9WGT51BDDL;
ChEMBL	ChEMBL4594401;
Chemical and physical data
Formula	C25H22N4O5
Molar mass	458.474 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C(C(=O)N(N1)C2=CC3=C(CCCC3)C=C2)N=NC4=CC=CC(=C4O)C5=CC=C(O5)C(=O)O;
	InChI InChI=InChI=1S/C25H22N4O5/c1-14-22(24(31)29(28-14)17-10-9-15-5-2-3-6-16(15)13-17)27-26-19-8-4-7-18(23(19)30)20-11-12-21(34-20)25(32)33/h4,7-13,28,30H,2-3,5-6H2,1H3,(H,32,33); Key:YATJUTCKRWETAB-UHFFFAOYSA-N;

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Hetrombopag (also known as rafutrombopag; trade name Hengqu) is a pharmaceutical drug for the treatment of thrombocytopenia and anemia.^[1]^[2]^[3]

It is a non-peptide small‐molecule thrombopoietin receptor agonist.^[4]

In China, it is approved for second-line treatment for primary immune thrombocytopenic purpura (ITP) and severe aplastic anemia (SAA) in adults.^[4]

References

^ Mei H, Chen X, Zhou J, Luo J, Shi Q, Liu J, et al. (January 2022). "Safety and efficacy of hetrombopag in patients with chronic immune thrombocytopenia: a single-arm, open-label, multi-center phase 1 study". Annals of Translational Medicine. 10 (2): 30. doi:10.21037/atm-21-4361. PMC 8848441. PMID 35282136.
^ Mei H, Liu X, Li Y, Zhou H, Feng Y, Gao G, et al. (February 2021). "A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia". Journal of Hematology & Oncology. 14 (1): 37. doi:10.1186/s13045-021-01047-9. PMC 7905908. PMID 33632264.
^ Chang H, Pan L, Jia Y, Xiang B, Huang X, Guo Y, et al. (2023). "Effectiveness and Safety of Hetrombopag-Containing Therapy in Patients with Severe Aplastic Anemia: A Multicenter Real-World Study". Blood. 142: 5631. doi:10.1182/blood-2023-185469.
^ ^a ^b Syed YY (September 2021). "Hetrombopag: First Approval". Drugs. 81 (13): 1581–1585. doi:10.1007/s40265-021-01575-1. PMID 34357499.

This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it.

[1] Mei H, Chen X, Zhou J, Luo J, Shi Q, Liu J, et al. (January 2022). "Safety and efficacy of hetrombopag in patients with chronic immune thrombocytopenia: a single-arm, open-label, multi-center phase 1 study". Annals of Translational Medicine. 10 (2): 30. doi:10.21037/atm-21-4361. PMC 8848441. PMID 35282136.

[2] Mei H, Liu X, Li Y, Zhou H, Feng Y, Gao G, et al. (February 2021). "A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia". Journal of Hematology & Oncology. 14 (1): 37. doi:10.1186/s13045-021-01047-9. PMC 7905908. PMID 33632264.

[3] Chang H, Pan L, Jia Y, Xiang B, Huang X, Guo Y, et al. (2023). "Effectiveness and Safety of Hetrombopag-Containing Therapy in Patients with Severe Aplastic Anemia: A Multicenter Real-World Study". Blood. 142: 5631. doi:10.1182/blood-2023-185469.

[Syed21-4] Syed YY (September 2021). "Hetrombopag: First Approval". Drugs. 81 (13): 1581–1585. doi:10.1007/s40265-021-01575-1. PMID 34357499.

[1]